Minimum Investment
About Company
Company Name: Avience Biomedicals Limited
Industry / Sector: Pharmaceuticals / Biotechnology / IVD & Diagnostics
Founded Year: 2024
Promoters: Dharam Deo Choudhary, Ram Nagina Choudhary, Janardan Pal, Deepa Choudhary
Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, rapid test kits, biochemistry analyzers, hematology analyzers, and other medical devices in the IVD (In-Vitro Diagnostics) segment. The company operates primarily in B2B and B2G markets serving pathology labs, hospitals, and research centers across India and overseas.
IPO Basic Details
| Company Name | Avience Biomedicals Limited |
| IPO Type | SME IPO |
| Price Band | ₹196 – ₹208 |
| Lot Size | 600 |
| Total Issue Size | ₹30.24 Cr (14,53,800 shares) |
IPO Strengths & Risks
Strengths
- Strong industry experience and expertise
- Diverse product portfolio across diagnostics and medical devices
- Strong distribution network in India and growing international presence
- Cost-effective and affordable solutions
- ISO certified with stringent quality control
Risks
- Highly competitive diagnostics and medical devices sector
- Regulatory approvals and compliance risks
- Raw material and supply chain dependencies
IPO Important Dates
| IPO Open Date | 18 Jun 2026 |
| IPO Close Date | 22 Jun 2026 |
| Basis of Allotment | 23 Jun 2026 |
| Refund Initiation | 24 Jun 2026 |
| Demat Credit Date | 24 Jun 2026 |
| Listing Date | 25 Jun 2026 |
| Anchor Investor Date | - |
| UPI Mandate Deadline | - |
IPO Objectives
- Capital expenditure for machinery and equipment – -
- Funding working capital requirements – -
- Debt repayment – -
- General corporate purposes – Balance amount
Investor Reservation
| QIB Quota | 49.83% (including Anchor) |
| Retail Quota | 35.08% |
| HNI Quota | - |
| Employee Quota | - |
| Shareholder Quota | - |
| Anchor Investor Allocation | - |
Market Lot Details
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 lots | 1200 | ₹2,49,600 |
| Retail Maximum | - | - | - |
| S-HNI Minimum | 3 lots | 1800 | ₹3,74,400 |
| S-HNI Maximum | - | - | - |
| B-HNI Minimum | 9 lots | 5400 | ₹11,23,200 |
Key Performance Indicators (KPI)
| ROE | 22.38% (Jan 31, 2026) |
| ROCE | 16.99% (Jan 31, 2026) |
| RoNW | - |
| PAT Margin | 15.86% (Mar 31, 2025) |
| EBITDA Margin | 24.70% (Jan 31, 2026) |
| EPS | - |
| NAV per share | - |
| Debt to Equity | 0.94 |
| P/E Ratio | - |
| Industry P/E | - |
Company Financial Data
| Period | Assets | Total Income | PAT | EBITDA | Net Worth | Borrowings |
|---|---|---|---|---|---|---|
| 31 Jan 2026 | 66.07 Cr | 41.94 Cr | 5.74 Cr | 10.34 Cr | 28.52 Cr | 26.73 Cr |
| 31 Mar 2025 | 56.52 Cr | 45.97 Cr | 7.23 Cr | 11.41 Cr | 22.78 Cr | 22.16 Cr |
| 31 Mar 2024 | 34.65 Cr | 24.37 Cr | 2.14 Cr | 4.08 Cr | 6.21 Cr | 15.13 Cr |
Grey Market Premium
| GMP Price | N/A (pre-listing) |
| Kostak Rate | N/A |
| Subject to Sauda | N/A |
| Last Updated | Jun 2026 |
| Estimated Listing Price | N/A |
IPO Subscription Data
| Total Subscription | Pending (IPO opens 18 Jun 2026) |
| QIB (Ex Anchor) | Pending |
| HNI Subscription | Pending |
| Retail Subscription | Pending |
| Anchor | - |
IPO Intermediaries
Registrar: Skyline Financial Services Pvt. Ltd.
Registrar Website: https://www.skylinerta.com/ipo.php
IPO Lead Manager(s)
Company Information
Address: C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi, Delhi 110058
Website: https://avienbio.com/
Email: info@avienbio.com
Phone: 1800-12-04-636
IPO Documents
Frequently Asked Questions (FAQ)
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.